Functional implications of modifying RyR-activating peptides for membrane permeability

*1Angela F. Dulhunty, 1Louise Cengia, 1Jacqui Young, 1Suzy M. Pace, 1Peta J. Harvey, 1,2Graham D. Lamb, 1,3Yiu-Ngok Chan, 1,3Norbert Wimmer, 1,3Istvan Toth & 1Marco G. Casarotto

1Division of Molecular Bioscience, John Curtin School of Medical Research, Australian National University, PO Box 334, Canberra, ACT 2601, Australia; 2The Department of Zoology, La Trobe University, Bundoora, Victoria, Australia and 3The School of Pharmacy, University of Queensland, Brisbane, Australia

Our aim was to determine whether lipoamino acid conjugation of peptides that are high-affinity activators of ryanodine receptor (RyR) channels would (a) render the peptides membrane permeable, (b) alter their structure or (a) reduce their activity. The peptides correspond to the A region of the II–III loop of the skeletal dihydropyridine receptor.

The lipoamino acid conjugation increased the apparent permeability of the peptide across the Caco-2 cell monolayer by up to ~20-fold.

Nuclear magnetic resonance showed that the z-helical structure of critical basic residues, required for optimal activation of RyRs, was retained after conjugation.

The conjugated peptides were more effective in enhancing resting Ca$^{2+}$ release, Ca$^{2+}$-induced Ca$^{2+}$ release and caffeine-induced Ca$^{2+}$ release from isolated sarcoplasmic reticulum (SR) than their un conjugated counterparts, and significantly enhanced caffeine-induced Ca$^{2+}$ release from mechanically skinned extensor digitorum longus (EDL) fibres.

The effect of both conjugated and unconjugated peptides on Ca$^{2+}$ release from skeletal SR was 30-fold greater than their effect on either cardiac Ca$^{2+}$ release or on the Ca$^{2+}$-Mg$^{2+}$ ATPase.

A small and very low affinity effect of the peptide in slowing Ca$^{2+}$ uptake by the Ca$^{2+}$-, Mg$^{2+}$ ATPase was exacerbated by lipoamino acid conjugation in both isolated SR and in skinned EDL fibres.

The results show that lipoamino acid conjugation of A region peptides increases their membrane permeability without impairing their structure or efficacy in activating skeletal and cardiac RyRs.

Keywords: Lipoamino acid conjugation; ryanodine receptor; sarcoplasmic reticulum; skeletal muscle; cardiac muscle; Ca$^{2+}$ release

Abbreviations: Caco-2, human colon carcinoma epithelial cell line; CICR, calcium-induced calcium release; DHPR, dihydropyridine receptor; EC coupling, excitation–contraction coupling; EDL, extensor digitorum longus; HBSS, Hanks' balanced salt solution; LC–MS, liquid chromatography–mass spectrometry; LHRH, luteinising hormone-releasing hormone; II–III loop, loop between the second and third membrane-spanning segment of the DHPR; $P_{app}$, apparent permeability coefficient; RyR, ryanodine receptor; SR, sarcoplasmic reticulum; TEER, trans-epithelial electrical resistance

Introduction

The ryanodine receptor (RyR) Ca$^{2+}$ release channel is the sole conduit for Ca$^{2+}$ release from internal stores in the sarcoplasmic reticulum (SR) to activate contraction in skeletal muscle and the heart. The RyR, either alone or in combination with the inositol 1,4,5-trisphosphate receptor (IP$_3$R), is also found in the endoplasmic reticulum, mitochondria, nuclear envelope and secretory vesicles of many cell types, including smooth muscle, neurones and lymphocytes. Despite the importance of this ion channel, there are few drugs available that can be used either as experimental probes for RyR activity or for therapeutic purposes.

A 20 amino-acid peptide (peptide $A$), corresponding to a part of the loop between the second and third membrane-spanning segment of the skeletal dihydropyridine receptor (DHPR), is a part of a naturally occurring muscle protein and is a high-affinity activator of skeletal and cardiac RyR channels (El-Hayek et al., 1995; Dulhunty et al., 1999; Gurrola et al., 1999; Lamb et al., 2000; Stange et al., 2001; Dulhunty et al., 2002). Both the DHPR and the RyR are essential for skeletal muscle contraction (Tanabe et al., 1988). A strict alignment (Block et al., 1988) allows physical coupling between the II–III loop of the DHPR and the RyR to initiate skeletal-type excitation–contraction (EC) coupling (which is independent of external Ca$^{2+}$). Although the $A$ region of the II–III loop is not required for EC coupling (Proenza et al., 2000; Wilkens et al., 2001), it has been implicated in the overall physical interaction between the DHPR and RyR (Ahern et al., 2001).
A sequence of positively charged residues (El-Hayek et al., 1995; Gurrola et al., 1999; Casarotto et al., 2000, 2001), and the alignment of the residues along one surface of the molecule (Casarotto et al., 2000; Green et al., 2003), are critical for peptide A to activate RyR channels. Modified A peptides having the most stable z-helical structure are the strongest activators of the RyR and have a surface orientation of positively charged residues similar to that in two scorpion toxins, Imperatoxin A and Maurocalcine (Mosbah et al., 2000; Green et al., 2003). The toxins, like the peptide, are high-affinity activators of the RyR and thought to bind to a similar site on the RyR (Tripathy et al., 1998; Gurrola et al., 1999; Green et al., 2003). The A peptides are potentially useful as probes for RyR channel activity and would be more useful if they could be modified for membrane permeability without loss of function.

In this study, we have made the A peptides membrane permeable by conjugating them to C_{12} or C_{10} lipoamino acids, to alter their physico-chemical properties. Lipoamino acids are z amino acids with long alkyl side-chains, which can enhance the membrane permeability, intestinal absorption and metabolic stability of peptides and have been investigated extensively in drug delivery (Toth et al., 1999; Toth & Keri, 2003). We have assessed the permeability of the lipoamino acid-conjugated A peptides, examined their structure and assessed their ability to release Ca^{2+} from cardiac and skeletal SR vesicles and from the SR in skinned skeletal muscle fibres. The results show that the lipid modification of the A peptides (a) increased their permeability, (b) did not significantly alter their structure, (c) enhanced their ability to activate Ca^{2+} release from isolated SR, (d) did not significantly alter their ability to activate the RyR in skinned muscle fibres and (e) enhanced a lower-affinity action of the peptide on Ca^{2+} uptake by the Ca^{2+}, Mg^{2+} ATPase in the SR.

Methods

Peptides and peptide synthesis

The A-series peptides, A1, A2, A1(D-R18) and A2(D-R18) (Table 1) were synthesised by the JCSMR Biomolecular Resource Facility using an Applied Biosystems 430A Peptide Synthesiser with purification to 98–100% using HPLC and mass spectroscopy. Stock peptide solutions (~2 mM) were prepared in H_{2}O and frozen in 20 μl aliquots (Dulhunty et al., 1999).

Lipid conjugation

Lipoamino acids, z-aminodecanoic acid and z-aminododecanoic acid were synthesised (Gibbons et al., 1999), purified, triturated with acetonitrile, then re-crystallised. The z-aminodecanoic acid was coupled to the resin once (or twice), then coupled to peptide A2 (D-R18) to yield A2(D-R18)-C_{10} (or A2(D-R18)-2C_{10}). Likewise, z-aminododecanoic acid was coupled once to A2(D-R18) to obtain A2(D-R18)-C_{12}. Sequences of A2 and A2(D-R18) and the lipoamino acid structures are:

\[
\begin{align*}
A2 & = TSAQKAKEERKKRMARGL \\
A2(D-R18) & = TSAQKAKEERKKM(D-R)GL \\
A2(D-R18)-C_{10} & = TSAQKAKEERKKM(D-R)GL \text{ and } \text{A2(D-R18)-C}_{10} \text{ - 2C}_{10} \text{- C}_{12} \\
\end{align*}
\]

Membrane permeability assessment

Caco-2 (human colon carcinoma; American Type Culture Collection) epithelial cell lines were cultivated as monolayers on permeable filters (Artursson & Karlsson, 1991). The cells were maintained in tissue culture flasks (Nunc, Roskilde, Denmark) and seeded at ~5 x 10^6 cells/cm^2 into 6.5 mm Transwells® with polycarbonate membranes (0.4 μm pore, Costar, Cambridge, U.S.A.). The culture medium (Dulbecco’s modified Eagle’s medium, Gibco Paisley, Scotland) was supplemented with 10% foetal calf serum, 1% nonessential amino acids, 1% L-glutamine and 1% penicillin and streptomycin. The media was replaced every 48 h, with 0.1 ml on the apical side and 0.6 ml on the basolateral side. Cells with a passage number of 55 were used in experiments. The integrity of the monolayers was monitored by the transepithelial electrical resistance (TEER) and mannitol permeability.

Apparent permeability

At 30 days after seeding, the cells were washed and equilibrated in Hanks’ balanced salt solution (HBSS) at 37°C on apical and basolateral sides. The cells were placed in new wells containing 0.6 ml of HBSS. In all, 200 μM of test compound was added to the apical side and the inserts transferred to new wells every 30 min over 3 h. Concentrations of test compounds in the basolateral solution were determined by liquid chromatography–mass spectrometry (LC–MS). The apparent permeability coefficient \( P_{app} \) (cm s^{-1}) was calculated as:

\[
P_{app} = (\Delta Q/\Delta t)/A \text{C}_0
\]

where \( \Delta Q/\Delta t \) is the permeability rate, \( A \) is the surface area of the monolayer and \( \text{C}_0 \) is the initial concentration of the peptide on the apical side. The mannitol permeability assay was performed using D-Mannitol-1-\(^{13}\)C, (Sigma) as described previously (Artursson et al., 2001).

Electrical measurements

TEER was measured at 37°C with a Millicell-electrical resistance system (ERS). The Caco-2 monolayers were incubated for 30 min, and the electrodes equilibrated for 15 min, in HBBS before TEER measurements 1 day and 30 min before, and immediately after, the experiment. The filter resistance without the cells (4–5 Ω cm^2) was subtracted from TEER values.
LC/MS analysis

A Perkin-Elmer Sciex API 3000 combined with Shimadzu HPLC was used to detect and measure peptides. A volume of 10 μl of HBBS/peptide sample was injected into the LC/MS. An Agilent C18 column (Zorbax 5 μm SB-C18 2.1 x 50 mm²) with C18 guard column and 1:10 splitter was used. Mobile phase A was 0.1% formic acid in H₂O, B was 90% acetonitrile with 0.1% formic acid. The solvent gradient was started with 0% B for 0.6 min, increased to 100% B at 1.6 min, retained for 1.9 min and decreased to 0% B in 0.1 min at a constant flow of 0.2 ml/min. Standards were prepared from 0.001 to 5 μM. Standard curves achieved R²>0.999.

Nuclear magnetic resonance (NMR) spectroscopy

Peptides A2(D-R18), A2(D-R18)-2C₁₀ and A2(D-R18)-C₁₂ were dissolved in 10% D₂O/90% H₂O to a final concentration of ~2 mM at pH ~5.5. NMR spectroscopy and subsequent analysis were then performed as described previously (Casarotto et al., 2000; 2001).

Isolation of SR vesicles

Skeletal SR was isolated from the back and leg muscles of New Zealand White rabbits, and heavy SR was collected from the 35–45% (w/v) interface of a discontinuous sucrose gradient, centrifuged and resuspended (Ahern et al., 1994). Cardiac SR was prepared from sheep heart (Chamberlain & Fleischer, 1988; Laver et al., 1995). Vesicles were frozen and stored either in liquid N₂ or at −70°C.

Ca²⁺ release

Extravesicular Ca²⁺ was monitored at 710 nm with the Ca²⁺ indicator, antipyrylazo III, using a Cary 3 spectrophotometer (Dullunty et al., 1999). Identical release experiments were performed at 790 nm, to detect Ca²⁺-independent changes in optical density (OD), which would alter the Ca²⁺ release measurement. The cuvette solution was stirred continuously and temperature controlled at 25°C. A typical Ca²⁺-release experiment is shown in Figure 3. Skeletal SR (100 μg of protein) was added to the cuvette solution (final volume of 2 ml), containing (mM): KH₂PO₄, 100 (pH = 7); MgCl₂, 4; Na₂ATP, 1; antipyrylazo III, 0.5). Ca²⁺, Mg²⁺-ATPase activity was suppressed with thapsigargin (200 nM; Sagara & Inesi, 1991). The same solutions were used with cardiac SR, except that an ATP-regenerating system – phospho(enol)pyruvate (5 mM) and pyruvate kinase (25 μg ml⁻¹) – was added. OD calibration curves were obtained daily. The same conditions were used for Ca²⁺ accumulation experiments, except that the concentration of antipyrylazo III was 0.2 mM. Control experiments, performed either without SR vesicles or when the SR vesicles were blocked with thapsigargin, ruthenium red and ionophore, showed that addition of the -2C₁₀ conjugated peptides elicited a step change in OD and then a slow increase. This artefactual change in OD was similar for all -2C₁₀ conjugated peptides, and increased with peptide concentration from negligible levels at ≤1 μM peptide to values equivalent to Ca²⁺ release rates of ~2 ± 0.3 and 64 ± 10 nmol mg⁻¹ min⁻¹ at 5 and 30 μM peptide, respectively. Measurements of Ca²⁺-release rate obtained in experiments where -2C₁₀ conjugated peptide was added to Ca²⁺-loaded vesicles were corrected for this artefact by subtracting the appropriate value. It was possible that this intrinsic optical effect was due to an isomer A2(D-R18)-2C₁₀. The peptide A2(D-R18) is made with optically pure L-amino acids and D-R18. The lipoamino acid (C₁₀) was a racemate (L-C₁₀ and D-C₁₀), so that one C₁₀ conjugation gave two diastereomers and the second coupling gave four diastereomers. These diastereomers were separated by HPLC and two major fractions obtained. Fraction 1 produced much less artefactual change in OD but retained its efficacy in activating Ca²⁺ release, while fraction 4 had less functional activity and produced a strong artefactual response.

Skinned fibre techniques

Experiments were performed at 23±2°C and chemicals obtained from Sigma, except where noted. Mechanically skinned segments of single extensor digitorum longus (EDL) muscle fibres from the rat were connected to a force transducer (AME801, SensoNor, Horten, Norway), and bathed in a standard high [K⁺] solution mimicking the normal environment (Lamb & Stephenson, 1994) and containing (mM): K⁺, 126; Na⁺, 37; 1,6-diaminohexane-N₂, N₂, N₂-tetraacetic acid (HDTA) (Fluka, Buchs, Switzerland), 50; total ATP, 8.0; total creatine phosphate, 10.0; total magnesium, 8.5; HEPES, 90; Na₂ATP, 1.0; total EGTA, 0.05, with pCa (i.e. −log₁₀[Ca²⁺]) 7.1 and pH 7.10±0.01 (free [Mg²⁺], 1 mM; osmolality, 295±5 mosmol kg⁻¹). The SR was fully emptied of Ca²⁺ by pre-equilibrating the fibre in standard solution with 0.5 mM EGTA (pCa>8) for 10 s and then exposing it to the Full Release Solution (similar solution with 30 mM caffeine, 0.05 mM free Mg²⁺ and 0.5 mM EGTA, pCa>8). The time integral (area) of the force response upon emptying the SR with the Full Release Solution indicated the amount of Ca²⁺ present in the SR (Lamb et al., 2001).

To test the sensitivity to 8 mM caffeine (e.g. Figure 9), the SR was loaded with Ca²⁺ to a set level (close to that in the fibre endogenously) by exposing the fibre for a set period (usually 15 s) to a solution buffered at pCa 6.7 with 1.0 mM total EGTA (Lamb et al., 2001). The fibre was then equilibrated in standard weakly Ca²⁺-buffered solution (1 mM Mg²⁺, 0.05 mM EGTA, pCa 7.1) for 20 s, with or without peptide, and exposed to a similar solution with 8 mM caffeine for 15 s, before fully depleting the SR of its remaining Ca²⁺ with the Full Release Solution. Maximum Ca²⁺-activated force in each fibre was determined using a 50 mM Ca²⁺-EGTA (pCa 4.7) (‘Max’) solution.

To examine the effect of a peptide on Ca²⁺ accumulation (Figure 10), the fibre was subjected to repeated load-deplete cycles in which the SR was loaded for a set period with peptide present or absent, and then emptied of all Ca²⁺ with the standard Full Release Solution (without peptide) to ascertain the total Ca²⁺ accumulated. When loading in standard 1 mM Mg²⁺, the load solution was at pCa 6.7 (1 mM total EGTA), but when loading at 10 mM Mg²⁺ the free [Ca²⁺] was increased to pCa 6.4. Before loading, the fibre was pre-equilibrated for 1 min in a solution with 0.5 mM EGTA (pCa>8) with or without peptide. To examine the Ca²⁺ sensitivity of the contractile apparatus, a fibre was exposed to matched sequences of solutions, both with and without the peptide, in which the [Ca²⁺] was heavily Ca²⁺-buffered.

British Journal of Pharmacology vol 144 (6)
(50 mM total EGTA replacing HDTA) at progressively higher levels (pCa 6.7–4.7) (Lamb & Stephenson, 1994). The steady-state force produced at each pCa was expressed relative to the respective maximum, and the force–pCa relationship was best fit with a Hill curve to give the pCa producing half-maximal force (pCa_{50}) and the Hill coefficient.

Statistics

Average data are given as mean±s.e.m. for n≥4, or mean±s.d. for n=3. The significance of the difference between control and test values was tested using a Student’s t-test.

Results

Membrane permeability of the peptides

The peptide sequences are shown in Table 1. The novel A2(D-R18) contained two modifications of the native A1 sequence, which increase structural stability. Ser17 was mutated to an alanine (Casarotto et al., 2000) and the L isomer of Arg18 was replaced by the D isomer (Green et al., 2003). The apparent permeabilities of A2(D-R18) and A2(D-R18)–2C_{10} were measured and compared with a single tail of the same chain length, A2(D-R18)–C_{10}. The amount of peptide transported across the Caco-2 cell monolayer increased with lipopamino acid conjugation (Figure 1a). The apparent permeabilities were 4.17±0.5E–08 cm s⁻¹ for A2(D-R18), 24.7±1.46E–08 cm s⁻¹ for A2(D-R18)–2C_{10} and 91.5±6.1E–08 cm s⁻¹ for the single -C_{10} conjugate.

The relatively small permeability for A2(D-R18)–2C_{10} was surprising, but is likely to reflect lower than expected concentrations in the donor compartment because the more hydrophobic peptide was adsorbed onto the surface of the sample well (Artursson & Karlsson, 1991). In contrast, since A2(D-R18)–C_{10} would have no significant plastic adsorption, its apparent permeability is a more accurate reflection of the true permeability of the tailed peptides. TEER values (Figure 1b) and the mannitol permeability assay indicated that the cells remained in good condition. TEER remained ≥30% of control in all cases. Toxicity is indicated by a fall to <10% of control (Ingels et al., 2002). A smaller fall in TEER over the experimental period with both the permeable and impermeable compounds was not indicative of toxicity.

Mannitol permeability, measured in parallel with compound permeability, remained between 2.4E–07 and 2.9E–07 cm s⁻¹ and well within the normal range of 1.8E–07 to 1.17E–06 (Artursson et al., 1996). Mannitol is restricted to the paracellular pathway across the tight junctions and its permeability indicates the tightness of the junction. The permeability will significantly increase if cells are damaged, as mannitol diffuses between the donor and the receiver compartments.

Since lipophylic compounds are excluded from paracellular pathways, it is well recognised that their permeability reflects their movement across the cell membranes, provided the cells are not damaged (Wong et al., 2002). Since TEER and mannitol permeability indicated that the cells in this study remained in good condition, the increase in permeability to cross Caco-2 cell membranes. (a) The apparent permeability of Caco-2 cell monolayers for peptides A2(D-R18), A2(D-R18)–C_{10} and A2(D-R18)–2C_{10}. Each bar show the mean±s.e.m. for P_{app} obtained from three experiments. The asterisks indicate a significant difference from data obtained with A2(D-R18). (b) Average TEER measurements obtained from the monolayer before and after permeability measurements using A2(D-R18) (n=3), A2(D-R18)–C_{10} (n=4) and A2(D-R18)–2C_{10} (n=4).

**Table 1** Effects of various A-series peptides on the initial rate of CICR from cardiac SR vesicles

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Relative release rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1 Thr Ser Ala Gin Lys Ala Glu Glu Arg Lys Arg Gly Leu</td>
<td>2.15±0.23* (4) 1.83±0.15* (9)</td>
</tr>
<tr>
<td>A2 Thr Ser Ala Gin Lys Ala Glu Glu Arg Lys Arg Gly Leu</td>
<td>2.03±0.03* (5) 2.61±0.34* (5)</td>
</tr>
<tr>
<td>A2(D-R18) Thr Ser Ala Gin Lys Ala Glu Glu Arg Lys Arg Gly Leu</td>
<td>3.02±0.50* (6) 2.77±0.39* (9)</td>
</tr>
<tr>
<td>A2(D-R18)–C_{10}</td>
<td>1.58±0.15 (3) 0.77±0.17 (3)</td>
</tr>
<tr>
<td>A2(D-R18)–2C_{10}</td>
<td>2.45±0.23* (3) 4.51±1.12* (4)</td>
</tr>
</tbody>
</table>

The rate of CICR in the presence of 10 or 30 μM peptide is expressed relative to that with no added peptide (control). Number of experiments is given in brackets. The sequence for each of the peptides is given. Residues altered from the native A1 sequence are highlighted. The Ser to Ala mutation in A2, A2(D-R18) is shown in bold type, and L-Arg to D-Arg replacement in A2(D-R18) is shown in bold italics. -C_{12} indicates that the peptide conjugated to a single -C_{12} tail, while -2C_{10} indicates conjugation to two -C_{10} tails. Asterisks indicate the data are significantly different from control (i.e. 1.0).
of the -C10 conjugates is indicative of increased membrane permeability.

**Structure of A2(D-R18) lipid-conjugated peptides**

The complete NMR assignments were determined using standard two-dimensional methods with TOCSY experiments (Bax & Davis, 1985) to identify spin types and NOESY experiments (Kumar *et al*., 1980) for specific sequence assignments. The extent of z-helical structure was assessed from NOE cross-peaks, which indicate that two proton atoms are separated by ~<5 Å. Adjacent amide backbone protons in an z-helix are separated by ~<2.8 Å and typical NOE patterns reflecting z-helical structure are shown in Figure 2.

The spectrum for **A2(D-R18)** (Figure 2a) indicates a helix extending throughout the entire peptide from residue 1 to 20, with a helical structure comparable to that in **A1(D-R18)** (Green *et al*., 2003). Fewer NOESY cross-peaks were present in the spectrum for the active fraction 1 of **A2(D-R18)-2C10** (Figure 2b). These cross-peaks, as well as the z-proton chemical shift, indicate a helical structure between residues 2 and 15 (Casarotto *et al*., 2001). Thus, the structures of the two residues closest to the lipophilic tail attachment were altered, but the key basic residues required for RyR activation (11–15) remained helical. Differences in the chemical shift patterns for **A2(D-R18)** and **A2(D-R18)-2C10** are due to environmental changes caused by the attachment of the lipoamino acid tail to the N-terminus.

The spectrum for the less active fraction 4 of **A2(D-R18)-2C10** (not shown) had the same number of NOE cross-peaks as fraction 1, but interestingly residues 11–15 were not fully contained within the helix. The loss of helical structure of residues 11–15 is (a) consistent with the low activity of fraction 4 (see Methods and Results) and (b) showed that isomerisation at the junction between the peptide and the lipid could cause small changes in peptide structure away from the conjugation point.

In contrast to the peptides **A2(D-R18)** and Fraction 1 of **A2(D-R18)-2C10**, **A2(D-R18)-C12** displayed an NOE cross-peak pattern indicative of a partial helical structure in the critical 11–15 amino-acid region (not shown). This may explain the reduced function of this peptide (Table 1), and is consistent with our hypothesis that this stretch of basic residues must be structurally ordered in a helical manner for optimal activation.

**Lipoamino acid conjugation enhances the ability of peptides to release Ca2+ from SR**

**Ca2+ release from skeletal SR** It was shown previously that mutating Ser 17 in the A1 peptide to an alanine (A2 peptide) increased its efficacy at inducing Ca2+ release from thapsigargin-blocked, skeletal SR (Casarotto *et al*., 2000). Furthermore, replacing the L isomer of Arg18 in A1 by the D isomer, to give **A1(D-R18)**, also increased the efficacy (Green *et al*., 2003) (e.g. see Figure 3). We show here that a peptide with both changes, **A2(D-R18)**, is even more effective than the peptides with either change alone (Figure 4). Importantly, when **A2(D-R18)** was double conjugated with -C10, to form **A2(D-R18)-2C10**, it became considerably more effective still, with the AC50 for resting Ca2+ release decreasing ~5-fold to ~3 μM and the maximum release rate more than doubling (Figure 4a). Furthermore, whereas **A2(D-R18)** did not evoke net release of Ca2+ in the absence of thapsigargin (Figure 3f), **A2(D-R18)-2C10** did so (Figure 3g).

Fractionation of **A2(D-R18)-2C10** yielded (a) an active isomer (fraction 1), which induced Ca2+ release with little intrinsic absorbance change (see Methods) and (b) a less active fraction 4, which had strong intrinsic effects. Resting Ca2+ release was similar for the racemic mixture and the active isomer at ≤20 μM (Figure 4a). The peptides also enhanced CICR and caffeine-induced Ca2+ release from the skeletal SR (Figure 4b). **A2(D-R18)-2C10** was more active than **A2(D-R18)** and there was a further increase in activity with fraction 1.

**Ca2+ release from cardiac SR** Both conjugated and unconjugated peptides were active on cardiac SR, but their effects were small and in marked contrast to the large effect on skeletal SR. The unconjugated **A2(D-R18)** at 30 μM had little, if any, effect on the rate of release from the thapsigargin-treated cardiac vesicles (Figure 5a). Interestingly, double -C10 conjugation of the peptide greatly increased its ability to induce resting Ca2+ release, with fraction 1 of **A2(D-R18)-2C10** apparently being more effective than the racemic mixture (Figure 5a). In contrast, similar lipoprotein conjugation of luteinising hormone-releasing hormone (LHRH), another small peptide with an unrelated sequence...
Thapsigargin addition to block the Ca\(^{2+}\) ionophore (A22187, ninth arrow). Release with 20 \(\mu M\) A2(D-R18) (sixth arrow), followed by 20 \(\mu M\) A2(D-R18) in (c) and 1.5 and 5.0 \(\mu M\) A2(D-R18)-2C10 (Figure 6c and d). In (d, e), the racemic (unfractionated) A2(D-R18)-2C10 (fraction 1 (F1) of A2(D-R18)-2C10 (n = 4–6). In (b), average data for 0.76 mM caffeine-induced Ca\(^{2+}\) release (left) or 10 \(\mu M\) Ca\(^{2+}\)-induced release (right) under control conditions (control, n = 4) and with 5 \(\mu M\) A2(D-R18) (n = 4), the racemic A2(D-R18)-2C10 (n = 4) and fraction 1 (F1) of A2(D-R18)-2C10 (n = 4). Note that the low [caffeine] was used to obtain a slope that was low enough to see a clear effect of the peptide.

Ruthenium red blocked CICR (Figure 6a and b) and Ca\(^{2+}\) release induced with 1 \(\mu M\) A2(D-R18)-2C10 (Figure 6c and d). [Ca\(^{2+}\)] did not fall after adding ruthenium red because Ca\(^{2+}\) pump activity was blocked by thapsigargin. A small residual release in ruthenium red was blocked by 10 mM Mg\(^{2+}\) (Figure 6f; 10 mM Mg\(^{2+}\) is a strong RyR antagonist — see skinned fibre results below). Similarly, Ca\(^{2+}\) release induced by 5 \(\mu M\) A2(D-R18)-2C10 was fully blocked by ruthenium red (Figure 6c), with the OD measurement showing only the small artefactual change caused by the conjugated peptides (see Methods).

**Lipoamino acid-conjugated peptides slow the rate of SR Ca\(^{2+}\) uptake** Lipoamino acid conjugation exacerbated an effect of the peptides on the Ca\(^{2+}\) pump. In skeletal SR, Ca\(^{2+}\) accumulation was measured after adding 50 \(\mu M\) Ca\(^{2+}\) to the cuvette (Figure 7a). The decline in [Ca\(^{2+}\)] (slope A, Figure 7a) reflected the net Ca\(^{2+}\) flux (uptake by the pump minus the efflux through the RyR). A2(D-R18)-2C10 was more effective than A2(D-R18) because it had a larger distance from the RyR.

**Figure 4** A2(D-R18)-2C10 enhances resting Ca\(^{2+}\) release, caffeine-induced Ca\(^{2+}\) release and Ca\(^{2+}\)-induced Ca\(^{2+}\) release from isolated skeletal SR. Average data are shown for rates of resting Ca\(^{2+}\) release (a) and caffeine-induced Ca\(^{2+}\) release or Ca\(^{2+}\)-induced Ca\(^{2+}\) release in (b). Rates of release are given in nmol mg\(^{-1}\) min\(^{-1}\). In (a), the vertical axis is split to display the rates of release with peptides A2 (n = 10), A1(D-R18) (n = 4–6) and A2(D-R18) (n = 4–6), as well as the greater rates of release with the racemic (unfractionated) A2(D-R18)-2C10 (n = 7–8) and the active isomer in fraction 1 (F1) of A2(D-R18)-2C10 (n = 4–6). In (b), average data for 0.76 mM caffeine-induced Ca\(^{2+}\) release (left) or 10 \(\mu M\) Ca\(^{2+}\)-induced release (right) under control conditions (control, n = 4) and with 5 \(\mu M\) A2(D-R18) (n = 4), the racemic A2(D-R18)-2C10 (n = 4) and fraction 1 (F1) of A2(D-R18)-2C10 (n = 4). Note that the low [caffeine] was used to obtain a slope that was low enough to see a clear effect of the peptide.
than the unconjugated A2(D-R18) in reducing Ca\(^{2+}\) accumulation (Figure 7b) - consistent with their relative effects on Ca\(^{2+}\) efflux. After adding ruthenium red, accumulation (slopes B and C, Figure 7) reflected Ca\(^{2+}\) uptake alone and was reduced minimally by 25 \(\mu\)M A2(D-R18) (second column), and reduced further by 5–10 \(\mu\)M A2(D-R18)–2C\(_{10}\). Notably, the decrease in Ca\(^{2+}\) uptake rate with the same peptide (second column), and for a control peptide (LHRH) with two -C10 tails (LHRH–2C\(_{10}\) (n = 2 each for RCR and CICR). Note, in panel b that there is some CICR even in the absence of any peptide.

The protocol was altered with cardiac SR because the SR failed to accumulate 50 \(\mu\)M Ca\(^{2+}\), but coped with a smaller pulse of 7.5 \(\mu\)M Ca\(^{2+}\) (Figure 8a and b). The effect of ruthenium red was small (Figure 8), indicating that the leak through the RyR was only small, most likely due to (a) there being excess longitudinal SR (which lacks RyRs), since the cardiac preparation was not fractionated by sucrose gradient (see Methods) and (b) low loading with addition of only 7.5 \(\mu\)M Ca\(^{2+}\). Thus, Ca\(^{2+}\) accumulation was dominated by Ca\(^{2+}\) uptake, even in the absence of ruthenium red. A2(D-R18) did not alter Ca\(^{2+}\) accumulation, nor did unconjugated A1 nor A2.
Figure 7. *A2(D-R18)-2C10* reduces Ca\(^{2+}\) accumulation by skeletal SR by increasing Ca\(^{2+}\) efflux through the RyR and by reducing Ca\(^{2+}\) uptake by the Ca\(^{2+}\), Mg\(^{2+}\) ATPase. (a) A record showing skeletal SR vesicles added to the cuvette (first arrow), followed by either H\(_2\)O (control) or peptide (second arrow). Ca\(^{2+}\) accumulation measured ~30 s after adding 50 \(\mu\)M Ca\(^{2+}\) (third arrow) (line A), and then after addition of ruthenium red (fourth arrow) to block the RyR (line B). When extravesicular Ca\(^{2+}\) was reduced to resting levels, a second bolus 50 \(\mu\)M Ca\(^{2+}\) was added (fifth arrow) and Ca\(^{2+}\) uptake measured (line C). The rate of accumulation after addition of ruthenium red (slopes B and C) reflected Ca\(^{2+}\) uptake by the Ca\(^{2+}\), Mg\(^{2+}\) ATPase. Average data corresponding to slopes A, B and C are given in (b–d), respectively. The first bin in each graph shows control data (with the volume of H\(_2\)O normally added with 25 \(\mu\)M peptide). The second bin shows data with 25 \(\mu\)M *A2(D-R18)*, while the third, fourth and fifth bins show data with 1, 5 and 10 \(\mu\)M *A2(D-R18)-2C10*, respectively. Each bin gives mean \pm s.d. for three observations. Asterisks indicate a significant difference from control.

Figure 8. *A2(D-R18)-2C10* inhibits Ca\(^{2+}\) uptake by the cardiac Ca\(^{2+}\), Mg\(^{2+}\) ATPase. (a, b) Records of a pair of experiments with cardiac SR vesicles. Either water (control) or peptide was added (not shown). Ca\(^{2+}\) accumulation was measured after each of two additions of 7.5 \(\mu\)M Ca\(^{2+}\) (lines 1 and 2, respectively) – (a) in the absence of ruthenium red (–RR); (b) ruthenium red added before Ca\(^{2+}\) (+ RR). (c) Average data under control conditions (with the volume of H\(_2\)O added with 30 \(\mu\)M peptide) and in the presence of the peptides. Four bins are shown under each condition: slope 1 (RR; 1+RR), slope 2 (RR; 2+RR), slope 1+RR (1+RR) and slope 2+RR (2+RR). The legend in (c) also applies to (d). The influence of RyR activity on uptake, that is, uptake in the presence of ruthenium red, was reduced to resting levels. These effects were consistent with (a) a minimal influence of Ca\(^{2+}\) efflux on the measurements and (b) inhibition of the pump by *A2(D-R18)-2C10* (Figure 8c and d). In contrast, the racemic *A2(D-R18)-2C10* at 2.5 \(\mu\)M slowed the decline in [Ca\(^{2+}\)] under all conditions to ~0.8 of control. These effects were consistent with (a) a minimal influence of Ca\(^{2+}\) efflux on the measurements and (b) inhibition of the pump by *A2(D-R18)-2C10*.

**Effects of lipoamino acid-conjugated peptides on skinned skeletal muscle fibres**

The unconjugated *A2(D-R18)* potentiated caffeine-induced Ca\(^{2+}\) release in skinned EDL fibres. The peptide was more effective than *A1(D-R18)* (Green et al., 2003), with 0.6 \(\mu\)M peptide increasing both the amplitude and rate of Ca\(^{2+}\) release.
the exposure to 8 mM caffeine. Strong partitioning into the contrast to Ca\textsuperscript{2+} was likely to cause too great a loss of Ca\textsuperscript{2+} equilibration period could not be increased because the peptide equilibration with the RyR was insufficient. (The 20 s peptide in skinned fibres. However, this was almost certainly conjugation seemingly reduced the relative effectiveness of the reversed after A2(D-R18)-2C10

**Table 2** Effect of peptides on the force response to 8 mM caffeine in rat skinned EDL fibres

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Test 1</th>
<th>Test 2</th>
<th>Rate of rise to 8 mM caffeine (% Ca\textsuperscript{2+}-activated maximum force per sec)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Peak response to 8 mM caffeine (% of maximum Ca\textsuperscript{2+}-activated force)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A2(D-R18) (0.6 μM) (n = 7)</td>
<td>19 ± 5.6</td>
<td>51 ± 5.6*</td>
<td>58 ± 10.2*</td>
<td>6 ± 1.8</td>
</tr>
<tr>
<td>A2(D-R18) (3 μM) (n = 4)</td>
<td>31 ± 9.6</td>
<td>79 ± 10*</td>
<td>77 ± 5.4*</td>
<td>9 ± 3.6</td>
</tr>
<tr>
<td>A2(D-R18)-2C10 (0.6 μM) (n = 5)</td>
<td>22 ± 12</td>
<td>37 ± 12*</td>
<td>52 ± 9.1*</td>
<td>12 ± 8.0</td>
</tr>
<tr>
<td>A2(D-R18)-2C10 (3 μM) (n = 3)</td>
<td>35 ± 9.3</td>
<td>59 ± 21</td>
<td>44 ± 20</td>
<td>12 ± 3.2</td>
</tr>
<tr>
<td>A2(D-R18)-2C10 (10 μM) (n = 3)</td>
<td>15 ± 15</td>
<td>74 ± 12.3*</td>
<td>84 ± 7.5*</td>
<td>2 ± 1.6</td>
</tr>
</tbody>
</table>

*Significant difference (P < 0.05) between control and test response (Student’s one-tailed paired t-test).

In each skinned fibre, the force response to 8 mM caffeine was measured twice in the absence of peptide (and averaged) and then twice in the presence of the peptide (tests 1 and 2) (see Figure 9), and expressed as a percentage of the maximum Ca\textsuperscript{2+}-activated force in that fibre. The table shows the mean ± s.e.m. data obtained in the indicated number of fibres (n). Note that, although the size of control response to 8 mM caffeine could differ somewhat between fibres, it was highly reproducible within a given fibre (e.g. Figure 9), and that paired control and test data were always obtained in each fibre.

A2(D-R18)-2C10 also potentiated caffeine-induced Ca\textsuperscript{2+} release in a skinned EDL fibre. A skinned EDL fibre was subjected to repeated cycles in which the SR was emptied of all Ca\textsuperscript{2+} and then reloaded to a set level and the responsiveness to 8 mM caffeine tested. The response to 8 mM caffeine was greatly potentiated by 10 μM A2(D-R18)-2C10. After testing the response to 8 mM caffeine, the SR was depleted of its remaining Ca\textsuperscript{2+} by exposure to the Full Release Solution, with the area of the resulting force response being indicative of the amount of Ca\textsuperscript{2+} that was in the SR. When 8 mM caffeine elicited a bigger force response, and hence more Ca\textsuperscript{2+} release, the amount of Ca\textsuperscript{2+} left in the SR decreased. Note that the ‘area’ of the force response to 8 mM caffeine cannot be directly compared to that when fully releasing the Ca\textsuperscript{2+} because of the very different levels of Ca\textsuperscript{2+} buffering in the two cases. The peptide was added 20 s before testing the responsiveness to 8 mM caffeine. ‘Max’ indicates maximum Ca\textsuperscript{2+}-activated force for the fibre.

(peak response 8 mM caffeine (% of maximum Ca\textsuperscript{2+}-activated force), rate of rise to 8 mM caffeine (% Ca\textsuperscript{2+}-activated maximum force per sec).)
theless, it is apparent that most of the reduction in net Ca$^{2+}$ uptake by the SR in a skinned EDL fibre when present in the loading solution. In (a), force responses were elicited when emptying the SR with the Full Release Solution after loading for the indicated time, under the standard conditions with 1 mM Mg$^{2+}$ (pCa 6.7, 1 mM total EGTA), with or without peptide. The area of the force response is indicative of the net amount of Ca$^{2+}$ loaded into the SR. The peptide reduced net Ca$^{2+}$ uptake and the effect became greater on successive repetitions (stabilising after ~3 repetitions) and was reversed only slowly by washout. The records shown are for the third repetition after loading in the presence of the peptide, and the following control records are for the fourth load/release cycle after washout of the peptide. In the fibre shown in (b), A2(D-R18)-2C10 caused only a small reduction in net SR Ca$^{2+}$ uptake when there was 10 mM free Mg$^{2+}$ in the loading solution. The reduced effect of the peptide was due to the high [Mg$^{2+}$] inhibiting activation of the Ca$^{2+}$ release channels and preventing the peptide from increasing Ca$^{2+}$ efflux from the SR during uptake. These findings indicate that most of the reduction in net Ca$^{2+}$ uptake by the peptide in (a) is due to increased Ca$^{2+}$ efflux, not reduced uptake. (Note that the rate of Ca$^{2+}$ uptake is reduced in 10 mM Mg$^{2+}$ but this effect was minimised by raising the [Ca$^{2+}$] in the load solution from pCa 6.7 to 6.4, so that the net Ca$^{2+}$ loaded into the SR is comparable with that in (a)). In (a, b) Ca$^{2+}$ release was evoked under the standard conditions with 1 mM Mg$^{2+}$.

Figure 10 Peptide A2(D-R18)-2C10 reduces net Ca$^{2+}$ uptake by the SR in a skinned EDL fibre when present in the loading solution. In (a), force responses were elicited when emptying the SR with the Full Release Solution after loading for the indicated time, under the standard conditions with 1 mM Mg$^{2+}$ (pCa 6.7, 1 mM total EGTA), with or without peptide. The area of the force response is indicative of the net amount of Ca$^{2+}$ loaded into the SR. The peptide reduced net Ca$^{2+}$ uptake and the effect became greater on successive repetitions (stabilising after ~3 repetitions) and was reversed only slowly by washout. The records shown are for the third repetition after loading in the presence of the peptide, and the following control records are for the fourth load/release cycle after washout of the peptide. In the fibre shown in (b), A2(D-R18)-2C10 caused only a small reduction in net SR Ca$^{2+}$ uptake when there was 10 mM free Mg$^{2+}$ in the loading solution. The reduced effect of the peptide was due to the high [Mg$^{2+}$] inhibiting activation of the Ca$^{2+}$ release channels and preventing the peptide from increasing Ca$^{2+}$ efflux from the SR during uptake. These findings indicate that most of the reduction in net Ca$^{2+}$ uptake by the peptide in (a) is due to increased Ca$^{2+}$ efflux, not reduced uptake. (Note that the rate of Ca$^{2+}$ uptake is reduced in 10 mM Mg$^{2+}$ but this effect was minimised by raising the [Ca$^{2+}$] in the load solution from pCa 6.7 to 6.4, so that the net Ca$^{2+}$ loaded into the SR is comparable with that in (a)). In (a, b) Ca$^{2+}$ release was evoked under the standard conditions with 1 mM Mg$^{2+}$.

(on the third repetition in peptide) (n = 6 fibres). The effect was slowly reversed by washout (taking ~10 min for near full recovery, legend to Figure 10). The effect of the peptide in reducing net Ca$^{2+}$ accumulation was consistent with it enhancing Ca$^{2+}$ efflux through the RyR during the Ca$^{2+}$-loading period. The greater effect with successive repetitions and slow washout are consistent with retarded equilibration of the peptide at its active site.

The possibility that the conjugated peptide also slowed Ca$^{2+}$ uptake by the Ca$^{2+}$ pump was examined by blocking Ca$^{2+}$ efflux with 10 mM free Mg$^{2+}$ - a potent inhibitor of the RyR (Lamb & Stephenson, 1994). Under such circumstances, 10 μM of A2(D-R18)-2C10 reduced net uptake to only 71 ± 8% of control (n = 6 fibres, P < 0.05) (e.g. Figure 10b). The fact that uptake still declined when the RyR was disabled indicates that the peptide directly inhibits the SR Ca$^{2+}$ pump. Nevertheless, it is apparent that most of the reduction in net Ca$^{2+}$ accumulation observed at normal [Mg$^{2+}$] (e.g. Figure 10a) was due to the peptide potentiating the Ca$^{2+}$ efflux from the SR during Ca$^{2+}$ loading. These results are in close accord with those found in the skeletal SR vesicles.

Discussion

We find that peptides, with sequences based on the A region of the skeletal muscle DHPR II-III loop, become permeable in a Caco-2 cell line assay following lipoamino acid conjugation. Importantly, the conjugation did not significantly alter the α-helical structure of residues that are critical for high-affinity activation of RyR Ca$^{2+}$ channels, and did not interfere with the ability of the peptides to release Ca$^{2+}$ from the SR. In fact, the conjugation increased the efficacy of the peptides in inducing Ca$^{2+}$ release from both skeletal and cardiac SR.

Permeability of lipoamino acid-conjugated peptides

As shown previously with other peptides (Wong et al., 2002), the lipoamino acid conjugation enhanced the ability of the poorly absorbed native peptides to cross the epithelial cell layer. In order for a compound to be well absorbed, it should have an apparent permeability in Caco-2 monolayers of ~1 x 10^-6 cm s^-1. Passive transport pathways across the epithelium are through tight junctions and across the apical and basolateral cell membranes (Artursson et al., 2001; Wong et al., 2002). The poorly permeable hydrophilic A2(D-R18) probably diffused through tight junctions, which provide the usual route for water-soluble compounds. The enhanced permeability of the hydrophobic lipoamino acid conjugates suggested that they crossed the cell membranes. The low apparent permeability of the more hydrophobic A2(D-R18)-2C10 (compared with A2(D-R18)-C10), can be explained by a lower than expected [peptide] in the donor solution, due to lower solubility and tendency to adsorb onto the chamber wall. High adsorbance can reduce apparent permeability by at least an order of magnitude (Artursson & Karlsson, 1991).

Structure of the conjugated peptides

The ability of the A peptides to stimulate Ca$^{2+}$ release through the RyR depends on the presence of a stretch of positively charged amino-acid residues along one surface of the α-helical...
peptide (Casarotto et al., 2000; 2001; Green et al., 2003). The profile of the NOESY spectra provides sufficient information to assess the integrity of secondary structure without performing a full structural analysis. The NOE cross-peak pattern in the amide region showed that the helical nature of the peptides was essentially retained despite the modification of the N-terminus by the lipoamino acid attachment. In particular, it was shown that the involvement of a helix for residues 11–15 was still a requirement in order for these peptides to release Ca\(^{2+}\) from the SR. This point was clearly evident for the two fractions of \(A2(D-R18)-2C_{10}\) where the stereochemistry related to the lipophilic attachment influenced the structure of the peptide portion and hence the functional response of the peptide. Thus, functional changes in the conjugated peptides can be attributed to the increased hydrophobicity of the peptide, rather than altered peptide structure.

**RyR activation by lipoamino acid-conjugated peptides**

The lipoamino acid conjugation of \(A2(D-R18)\) considerably enhanced its ability to release Ca\(^{2+}\) from isolated SR. Since the control \(LHRH-2C_{10}\) peptide did not release Ca\(^{2+}\) or enhance CICR, the lipoamino acid tails *per se* did not contribute to Ca\(^{2+}\) release.

**Different actions of the peptides on skeletal and cardiac SR**

The effects of the A peptides on skeletal SR were significantly stronger than the effects on cardiac SR. The lower sensitivity of the cardiac preparation presumably reflects differences between the binding sites or in the environment of the binding site in different RyR isoforms. A further reflection of possible differences in the environment of the binding site is the fact that the active fraction 1 (F1) of \(A2(D-R18)-2C_{10}\) was as effective as the racemic \(A2(D-R18)-2C_{10}\) in releasing Ca\(^{2+}\) in the skeletal preparation, but was substantially more effective in the cardiac preparation (although its effect remained far less than that on skeletal SR).

**Slow equilibration of lipoamino acid-conjugated peptides in skinned fibres**

In contrast to the greater efficacy of the lipoamino acid-conjugated peptides in releasing Ca\(^{2+}\) from isolated SR, \(A2(D-R18)-C_{10}\) was less effective in enhancing caffeine-induced Ca\(^{2+}\) release in skinned fibres when equilibration times were brief (≈ 20 s). However, when the preparation was successively exposed to \(A2(D-R18)-C_{10}\) (with 1 min equilibration during each exposure), a progressively greater effect on Ca\(^{2+}\) accumulation was observed, which was attributed to enhanced Ca\(^{2+}\) efflux. This indicated that equilibration of the conjugated peptide at its active site was slower than accumulation of the unconjugated peptide. Slow equilibration is consistent with the hydrophobic peptide partitioning into the lipid of the t-tubule and SR membranes that surround the RyR and form two boundaries of the restricted space of the triad junction (Franzini-Armstrong, 1970), as seen in the skinned fibres with other lipid-permeable agents such as nifedipine (Posterino & Lamb, 1998). It is also evidence that the conjugated peptides readily permeate the cell membranes of muscle fibres.

**Lipoamino acid conjugation of the A peptides reveals an action on the Ca\(^{2+}\) pump**

A small and low-affinity effect of the conjugated A peptides on the Ca\(^{2+}\), Mg\(^{2+}\) ATPase was apparent. Since fast-twitch skeletal and cardiac SR contain different isoforms of SR, endoplasmic reticulum Ca\(^{2+}\) ATPase (SERCA), SERCA1 and SERCA2a, respectively (MacLennan et al., 1997), the effect is not isoform specific. A small decline in Ca\(^{2+}\) uptake by skeletal SR exposed to the unconjugated \(A2(D-R18)\) suggested that the hydrophilic peptide may have restricted access to an inhibitory site located in a hydrophobic region of the protein.

**Potential use for lipoamino acid-conjugated A peptides**

Within a limited concentration range, \(A2(D-R18)-2C_{10}\) is a specific activator of the skeletal RyR in SR vesicles and skinned fibres. \(A2(D-R18)-2C_{10}\) at 2 \(\mu\)M produced an ≈ 2000-fold increase in Ca\(^{2+}\) release from skeletal SR without affecting the Ca\(^{2+}\) pump. At higher concentrations where small effects on the cardiac RyR and on Ca\(^{2+}\) uptake by the Ca\(^{2+}\), Mg\(^{2+}\) ATPase were apparent, the activation of RyR1 was several orders of magnitude greater than the effects on RyR2 or the SERCA proteins. The peptide at 20 \(\mu\)M caused a 20,000-fold increase in Ca\(^{2+}\) release from skeletal SR, compared with only a four-fold reduction in Ca\(^{2+}\) uptake. The peptide enhanced caffeine-induced Ca\(^{2+}\) release in skinned fibres at 0.6 \(\mu\)M, and at 10 \(\mu\)M increased caffeine-induced Ca\(^{2+}\) release ≈ 6-fold with only a 30% decline in pump activity. Therefore, \(A2(D-R18)-2C_{10}\) is a membrane-permeable peptide that selectively activates Ca\(^{2+}\) release from skeletal SR through RyR channels at concentrations ≈ 2 \(\mu\)M.

In conclusion, the experiments show that lipoamino acid conjugation renders the A peptides membrane permeable, without significantly altering either the \(z\)-helical secondary structure of a critical region of the peptides or altering their ability to stimulate RyR activity. The present study constitutes proof of principal that lipoamino acid conjugation of A peptides is a potentially promising method for developing membrane-permeable specific stimulators of RyRs for use *in vivo*.

We are grateful to Joan Stivala for assistance with SR vesicle preparation and characterisation and Maria Cellini for help with the skinned fibre experiments. This work was supported by Australian NHMRC Project Grant #224237 and the National Heart Foundation of Australian (# G 01C 0296).
References


(Received June 1, 2004 Revised July 30, 2004 Accepted August 23, 2004)